{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chronic-obstructive-pulmonary-disease/prescribing-information/inhaled-corticosteroids/","result":{"pageContext":{"chapter":{"id":"10bec3db-4371-5d92-a5e9-4f2300029732","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids","depth":2,"htmlHeader":"<!-- begin field ea1b6918-69e0-4e4f-b172-7fd473f92111 --><h2>Inhaled corticosteroids</h2><!-- end field ea1b6918-69e0-4e4f-b172-7fd473f92111 -->","summary":"","htmlStringContent":"<!-- begin item ccf304a1-e8e8-465c-940b-34c93b3ff530 --><!-- end item ccf304a1-e8e8-465c-940b-34c93b3ff530 -->","topic":{"id":"8e2a563d-c3b1-5ed5-a460-de2b3ffc8c0f","topicId":"e48489e8-63d1-4a04-bc5b-07e36a76af58","topicName":"Chronic obstructive pulmonary disease","slug":"chronic-obstructive-pulmonary-disease","lastRevised":"Last revised in October 2020","chapters":[{"id":"8441dfb8-d2f6-511c-abf6-23d0c8a600d0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5ccd2981-1bc9-5357-86d2-cbf578b57adb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2eb66d0c-0e3f-55c2-bb2f-ba47fdbd1bfd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8f4eeb38-3744-5824-a90c-82b0b8906580","slug":"changes","fullItemName":"Changes"},{"id":"f2cfeec1-2d2a-5d22-b569-42eb61ba7caa","slug":"update","fullItemName":"Update"}]},{"id":"d28cbe2c-ffc9-58ab-913c-3afa52c28841","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"99f07881-2c1a-5874-8cd2-3f10dcb385fa","slug":"goals","fullItemName":"Goals"},{"id":"85c2e06f-fe1e-532b-8752-0337ca19cfe3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f6fa4f07-a45d-5c3e-8c59-2054ea5ecd38","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"defe1786-7b6d-5c90-a7f4-0871262dd84f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e6356570-e32f-5480-89d6-026b80bb055d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0433c46f-8e2f-53b3-a392-aca635b35160","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"29a2fdef-c0c3-5bb6-9c12-21d649ed27bb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"715af617-76e1-5846-9262-1616f0003270","slug":"definition","fullItemName":"Definition"},{"id":"6f383baf-ff39-58db-b933-24b4c5feb5f8","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"7fe9ff8f-68ba-5f97-91ab-8d23c907b1cf","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4bcdbaec-2487-5733-812a-7ec514939f8d","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c7c94e20-91a7-5b3d-b8dd-0d4f8d5c023c","slug":"complications","fullItemName":"Complications"}]},{"id":"844f6e5f-bd6a-5d1d-8f3e-0980e52cd744","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"aa2453ae-c791-521b-9ead-ca40d5efae00","slug":"diagnosis-copd","fullItemName":"Diagnosis - COPD"},{"id":"93fac9cc-fc19-5440-8330-f6f56941ddb6","slug":"diagnosis-acute-exacerbation","fullItemName":"Diagnosis - acute exacerbation"}]},{"id":"b513a018-d7cf-53a1-9748-c7fa367312d0","fullItemName":"Management","slug":"management","subChapters":[{"id":"4aafe1b6-b17a-51d8-a8f0-104880ac3722","slug":"stable-copd","fullItemName":"Scenario: Stable COPD"},{"id":"ef02510d-99b8-561a-b40c-8bfaab787b88","slug":"acute-exacerbation","fullItemName":"Scenario: Acute exacerbation"},{"id":"22cd95c6-b76a-5e58-8329-cfed9e9bf26e","slug":"end-stage-copd","fullItemName":"Scenario: End-stage COPD"},{"id":"f1d4be42-b98a-55de-860a-3be931c97c1c","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"6e9178ad-4f96-5153-b348-f5f0f9132463","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"651db25c-bc72-5eaa-b790-e5c86053d13c","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"51f6354b-2f19-59ca-889c-a9497e0223fc","slug":"muscarinic-antagonists","fullItemName":"Muscarinic antagonists"},{"id":"10bec3db-4371-5d92-a5e9-4f2300029732","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"f45aa048-e0b1-55dc-9f40-68f5af6d3b61","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"1f101b12-c624-5d0c-9b55-c7fa2d40a3ed","slug":"mucolytics","fullItemName":"Mucolytics"},{"id":"669a5030-cc7b-5a64-ba03-f05ca2dd60f3","slug":"theophylline","fullItemName":"Theophylline"},{"id":"2006f9b1-cca0-50cd-9c1e-99a6316048e4","slug":"antibiotics","fullItemName":"Antibiotics"}]},{"id":"81fd9c2f-91c3-5726-b50a-85fc169646d3","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6b91263e-7dc1-51aa-9976-bd92619d846e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ac29e092-9d36-550e-99e2-c6b478d21c00","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"737d1a20-607a-560b-8522-2ddb2237249b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bec938e3-108f-5f91-9c9b-2c289bae4e07","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"dc4c2f7c-85ce-5ba5-a2ef-149ee8a9d54d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"51ecdba0-ee93-5792-af12-b38cb8f06b8c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9ad1cd46-bf5b-505f-a6d9-bad7287adccc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6e9178ad-4f96-5153-b348-f5f0f9132463","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"e5a3d58b-9054-5b97-97f2-3b6ad6e756e6","slug":"dose-of-inhaled-corticosteroid","fullItemName":"Dose of inhaled corticosteroid","depth":3,"htmlHeader":"<!-- begin field 261910ed-30fa-4335-bbbd-7bc261318029 --><h3>What inhaled corticosteroids are available for COPD, and what dose should I prescribe?</h3><!-- end field 261910ed-30fa-4335-bbbd-7bc261318029 -->","summary":"","htmlStringContent":"<!-- begin item c1fc8fc6-7540-4b5e-8fc5-ab3a9371a0a5 --><!-- begin field a3023fe4-5d95-403a-80af-3bea64b65d1b --><ul><li>Inhaled corticosteroids (ICS) should be prescribed in combination with a long-acting bronchodilator in people with chronic obstructive pulmonary disease (COPD).</li><li>The NICE guideline on COPD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>] recommends that where combination therapy with long-acting bronchodilators and ICS is being considered, clinicians should be aware of, and discuss with the person, the risk of adverse effects including an increased risk of pneumonia (which may require hospitalization).</li></ul><p style=\"margin-left:18.0pt;\"><strong>Inhaled corticosteroid preparations licensed for the management of COPD are available as combination products. They include:</strong></p><ul><li><strong>Formoterol with budesonide</strong><ul><li><strong>DuoResp Spiromax® 160/4.5 </strong>— for COPD with FEV1 <70% of predicted — by inhalation of powder, 2 inhalations twice daily.</li><li><strong>Symbicort Turbohaler® 400/12</strong> — for COPD with FEV1 <70% of predicted — by inhalation of powder, one puff twice daily.</li><li><strong>Fobumix® 160/4.5 Easyhaler</strong> — for COPD with FEV1 <70% of predicted — by inhalation of powder, 2 inhalations twice daily.</li><li><strong>DuoResp Spiromax ® 320/9</strong> — for COPD with FEV1 <70% of predicted — by inhalation of powder, 1 inhalation twice daily.</li><li><strong>Fobumix® 320/9 Easyhaler9</strong> — for COPD with FEV1 <70% of predicted — by inhalation of powder, 1 inhalation twice daily.</li><li><strong>Symbicort® 200/6 pressurised inhaler — </strong>for COPD with FEV1 <70% of predicted — by inhalation of aerosol, 2 inhalations twice daily.</li><li><strong>Symbicort 200/6 Turbohaler®</strong> — for COPD with FEV1 <70% of predicted — by inhalation of powder, 2 puffs twice daily.</li><li>Other combinations of formoterol with budesonide are available but are not currently licensed for use in COPD.</li></ul></li><li><strong>Formoterol with beclometasone</strong><ul><li><strong>Fostair NEXThaler® 100/6— </strong>for COPD with FEV1 <50% predicted by inhalation of powder, 2 inhalations twice daily.</li><li><strong>Fostair® 100/6 — </strong>for COPD with FEV1 <50% predicted by inhalation of aerosol — 2 inhalations twice daily.</li><li>Clinicians should be aware that Fostair® is more potent than traditional beclometasone dipropionate CFC-free inhalers — dose of beclometasone dipropionate in Fostair® should be lower than non-extra-fine formulations and will need to be adjusted to the individual.</li></ul></li><li><strong>Formoterol with beclometasone and glycopyrronium</strong><ul><li>For moderate to severe COPD by inhalation of aerosol — 2 inhalations twice daily.</li></ul></li><li><strong>Salmeterol with fluticasone</strong><ul><li><strong>Seretide 500 Accuhaler®</strong> — by inhalation of powder, one inhalation twice daily.</li><li><strong>AirFluSal Forspiro® </strong>— for COPD with FEV1 <60% of predicted by inhalation of powder, 1 inhalation twice daily.</li><li>Other combinations of salmeterol with fluticasone are available but are not currently licensed for use in COPD.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018o</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018i</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018k</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2019c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>]</p><!-- end field a3023fe4-5d95-403a-80af-3bea64b65d1b --><!-- end item c1fc8fc6-7540-4b5e-8fc5-ab3a9371a0a5 -->","subChapters":[]},{"id":"63684c79-868e-5b6a-ac3b-6023230f02a8","slug":"cautions-adverse-effects-interactions","fullItemName":"Cautions, adverse effects, interactions","depth":3,"htmlHeader":"<!-- begin field 4b2d3e54-b163-4bcc-a29c-47f0c022af57 --><h3>What are the contraindications, cautions, adverse effects, drug interactions, and recommended monitoring for inhaled corticosteroids?</h3><!-- end field 4b2d3e54-b163-4bcc-a29c-47f0c022af57 -->","summary":"","htmlStringContent":"<!-- begin item 44346a6d-9bf3-4210-86ad-47ea973e9480 --><!-- begin field 41aa5cef-a0f1-4453-b754-68abdd954442 --><ul><li><strong>For detailed prescribing information on inhaled corticosteroids</strong>, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-inhaled/\">Corticosteroids - inhaled</a>.</li><li><strong>Clinicians should be aware of the increased risk of pneumonia</strong> (including pneumonia requiring hospitalisation) in people with chronic obstructive pulmonary disease treated with inhaled corticosteroids – this should be discussed with the person before prescribing.</li><li><strong>Consider issuing a steroid treatment card to:</strong><ul><li>People using prolonged high doses of inhaled corticosteroids.</li><li>People taking inhaled corticosteroids plus drugs that inhibit their metabolism (for example cytochrome P450 inhibitors, such as HIV protease inhibitors).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>]</p><!-- end field 41aa5cef-a0f1-4453-b754-68abdd954442 --><!-- end item 44346a6d-9bf3-4210-86ad-47ea973e9480 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}